The landscape of prostate cancer treatment is undergoing a seismic shift, particularly for patients facing the daunting reality of biochemical recurrence (BCR). As clinical practice moves toward more nuanced, risk-stratified approaches, the phase III EMBARK trial (NCT02319837) has emerged as a cornerstone of evidence-based management. Recently, lead investigators Dr. Stephen Freedland of Cedars-Sinai Medical Center and Dr. Ugo De Giorgi of the University of Salento convened for a detailed, multi-part podcast series to unpack the profound clinical implications of the EMBARK data, focusing on secondary analyses that offer a roadmap for personalized patient care.
Main Facts: The EMBARK Paradigm
The EMBARK trial was designed to address a critical gap in oncology: how to best manage patients with high-risk biochemically recurrent prostate cancer—a state often characterized by a rapid rise in prostate-specific antigen (PSA) levels following initial surgery or radiation, but without visible metastases on conventional imaging (CT and bone scan).
The trial’s primary objective was to evaluate the efficacy of enzalutamide—a potent androgen receptor pathway inhibitor (ARPI)—both in combination with leuprolide (an androgen deprivation therapy, or ADT) and as a monotherapy, compared to the traditional standard of care, leuprolide alone.
The findings were definitive: the combination of enzalutamide and leuprolide significantly improved metastasis-free survival (MFS) and demonstrated a meaningful improvement in overall survival. While enzalutamide monotherapy also showed efficacy, the combination therapy proved to be a superior strategy for extending survival and delaying the progression to metastatic disease. Crucially, these benefits were achieved while preserving the patients’ quality of life, a primary concern for men navigating the long-term journey of prostate cancer treatment.
Chronology of Evidence
The journey of the EMBARK trial has unfolded in distinct, vital stages, each layer of data providing more clarity for clinicians:
- Initial Design and Rationale: The trial was launched to establish whether early intervention with ARPIs could stave off the progression of high-risk BCR.
- Primary Efficacy Outcomes: Early publications confirmed that both the combination and monotherapy arms significantly extended metastasis-free survival compared to ADT alone, establishing a new benchmark for "conventional-imaging-negative" (CIN) disease.
- Long-Term Survival Data: Recent updates revealed a dramatic improvement in overall survival for the combination arm. While monotherapy showed numerical improvements in survival, it did not reach the threshold for statistical significance, underscoring the strength of the combination approach.
- Subsequent Analyses: The most recent phase of the EMBARK series—the focus of the latest expert discussion—dives into secondary endpoints: efficacy across age groups, the impact of prior definitive therapies, the definition of high-risk BCR, and patient-reported outcomes during treatment suspension.
Supporting Data: Efficacy and Quality of Life
The subsequent analyses of EMBARK provide a granular look at how different cohorts respond to treatment. According to Dr. De Giorgi, the clinical benefits of enzalutamide—with or without leuprolide—extend well beyond basic survival metrics.
Clinical Efficacy across Subgroups
Patients treated with the combination therapy saw significant delays in the time to distant metastasis, the resumption of subsequent hormonal therapies, castration resistance, symptomatic progression, and the first symptomatic skeletal event. These benefits remained consistent regardless of whether the patient had undergone prior radical prostatectomy, radiation therapy, or a combination of both.
Notably, age did not dampen the efficacy of the treatment. While serious adverse events (SAEs) were naturally more prevalent in patients aged 70 and older, the incidence of treatment-related SAEs remained relatively low across all age brackets, suggesting that the therapy is both effective and manageable for an aging patient population.
PSA Dynamics and Outcomes
A vital marker for success in the trial was the achievement of undetectable PSA levels (defined as <0.2 ng/mL) by week 36. Patients who reached this milestone were able to suspend treatment, and the data showed that those who achieved a second period of undetectable PSA following the reinitiation of therapy experienced longer MFS. This highlights the value of monitoring PSA response as a surrogate for long-term control.
Patient-Reported Outcomes (PROs)
One of the most common anxieties regarding long-term cancer therapy is the impact on quality of life. Dr. Freedland highlighted that patients who suspended treatment during the trial did not report a sudden "jump" in quality of life, which is explained by the fact that the treatment itself did not cause a meaningful decline in quality of life during the active phase.
However, a distinct advantage was noted for monotherapy: the preservation of sexual function. Because monotherapy allows for the maintenance of testosterone levels, patients experienced better-preserved interest in sex, erectile function, and overall satisfaction compared to those on combination therapy or ADT alone. This presents a compelling option for patients for whom sexual health is a priority, provided they are monitored for potential breast-related side effects such as gynecomastia.
Implications for Clinical Practice: The Role of PSMA-PET
Perhaps the most pressing question for contemporary clinicians is how to integrate molecular imaging, specifically PSMA-PET, into the management of high-risk BCR.
"Imaging is here to stay," Dr. Freedland noted. The shift toward PSMA-PET has revealed that many patients previously classified as "negative" on conventional imaging actually harbor occult metastases. Recent studies indicate that in patients with high-risk BCR, PSMA-PET can detect metastatic disease in up to 37–70% of cases, depending on the prior treatment (surgery vs. radiation).
Risk-Stratified Decision Making
The experts advocate for a risk-adapted approach. While observation remains appropriate for low-risk BCR patients, those with high-risk features benefit from systemic therapy with enzalutamide. For those who are identified as having oligometastatic disease (a small number of visible lesions on a PSMA-PET scan), a multidisciplinary approach—combining systemic therapy with metastasis-directed therapy (MDT), such as stereotactic body radiotherapy—is increasingly becoming the standard of care.
The Question of Prophylaxis
For patients choosing monotherapy to preserve sexual function, clinicians must address the risk of breast-related side effects caused by the aromatization of testosterone into estrogen. Dr. De Giorgi and Dr. Freedland emphasized that while specific enzalutamide-related prophylactic data are still emerging, using prophylactic tamoxifen or breast irradiation—strategies borrowed from bicalutamide management—is a prudent, proactive clinical step.
Official Responses and Expert Conclusion
The EMBARK trial has effectively rewritten the treatment guidelines for high-risk biochemically recurrent prostate cancer. By validating the use of enzalutamide in combination with leuprolide as a powerful tool for extending survival, the trial has moved the field away from passive observation toward active, effective systemic management.
Both Dr. Freedland and Dr. De Giorgi emphasize that the future of prostate cancer care lies in the "shared decision-making" model. Clinicians must weigh the clinical benefits of combination therapy against the potential quality-of-life advantages of monotherapy, all while utilizing the latest in PSMA-PET imaging to determine the exact extent of disease.
As these findings continue to permeate clinical practice, the key takeaway remains consistent: early, aggressive, and highly individualized treatment is the most effective way to combat the progression of high-risk prostate cancer. The EMBARK trial provides not only the evidence base but the confidence for physicians to offer these life-extending therapies to their patients.
Disclaimer: This article is based on the findings presented in the Future Oncology publication and the accompanying EMBARK podcast series. The content reflects the professional medical opinions of the investigators, Dr. Stephen J. Freedland and Dr. Ugo De Giorgi. All clinical decisions should be made in consultation with a qualified medical professional, considering individual patient history and current institutional guidelines.
About the Author
